Impact of induction treatment before autologous stem cell transplantation on long‐term outcome in patients with newly diagnosed multiple myeloma
Clinical trials for patients with multiple myeloma (MM) using novel agent (NA)‐based regimens before autologous stem cell transplantation (SCT) have shown improvement in response rates and progression‐free survival (PFS); however they have failed to identify a significant overall survival (OS) benefit. The aim of this study was to analyze the potential impact of initial induction on the feasibility and outcome of subsequent treatment lines in a real clinical practice setting.
No Supplementary Data
No Article Media